Therapeutic dose of nebivolol, a nitric oxide-releasing β-blocker, reduces atherosclerosis in cholesterol-fed rabbits

Filomena de Nigris, Francesco Paolo Mancini, Maria Luisa Balestrieri, Russell Byrns, Carmela Fiorito, Sharon Williams-Ignarro, Antonio Palagiano, Ettore Crimi, Louis J. Ignarro, Claudio Napoli

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Nitric oxide (NO) exerts a plethora of vascular beneficial effects. The NO-releasing β-blocker nebivolol is a racemic mixture of d/l-enantiomers that displays negative inotropic as well as direct vasodilating activity. The in vivo antiatherogenic activity of therapeutic doses of the β-blocker with antioxidant properties carvedilol (12.5 mg/day) or nebivolol (5 mg/day) was tested in cholesterol-fed rabbits. Animals received a 1% cholesterol-rich diet alone (controls) or mixed with drugs (treated animals) for 8 weeks. While it did not affect hyperlipidemia, nebivolol inhibited the development of atherosclerosis, expressed as computer-assisted imaging analysis of aortic area covered by lesions (23.3 ± 4.1% in treated vs 38.2 ± 6.4% in control animals, p <0.01). Differently, in our experimental condition of therapeutic drug doses, this antiatherogenic effect did not reach statistical significance in rabbits treated with carvedilol (32.5 ± 5.1% aortic area covered by lesions, p = NS vs controls). Plasma nitrates increased in rabbits treated with nebivolol while both β-blockers reduced LDL oxidation. Moreover, nebivolol induced a consistent increase of endothelial reactivity and aortic eNOS expression compared with control animals (p <0.05) and those receiving carvedilol (p <0.05). Since NO may exert beneficial effects in atherosclerosis, a NO-dependent mechanism could explain this data. These observations suggest that the NO-releasing β-blocker, nebivolol, might represent an effective pharmacological approach for preventing atherosclerotic lesion progression.

Original languageEnglish
Pages (from-to)57-63
Number of pages7
JournalNitric Oxide - Biology and Chemistry
Volume19
Issue number1
DOIs
Publication statusPublished - Aug 2008

Fingerprint

Nebivolol
Atherosclerosis
Nitric Oxide
Cholesterol
Rabbits
Animals
Therapeutics
Enantiomers
Nutrition
Hyperlipidemias
Pharmaceutical Preparations
Nitrates
Blood Vessels
Antioxidants
Pharmacology
Diet

Keywords

  • Atherosclerosis
  • Carvedilol
  • Nebivolol
  • Nitric oxide
  • Rabbit

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Therapeutic dose of nebivolol, a nitric oxide-releasing β-blocker, reduces atherosclerosis in cholesterol-fed rabbits. / de Nigris, Filomena; Mancini, Francesco Paolo; Balestrieri, Maria Luisa; Byrns, Russell; Fiorito, Carmela; Williams-Ignarro, Sharon; Palagiano, Antonio; Crimi, Ettore; Ignarro, Louis J.; Napoli, Claudio.

In: Nitric Oxide - Biology and Chemistry, Vol. 19, No. 1, 08.2008, p. 57-63.

Research output: Contribution to journalArticle

de Nigris, F, Mancini, FP, Balestrieri, ML, Byrns, R, Fiorito, C, Williams-Ignarro, S, Palagiano, A, Crimi, E, Ignarro, LJ & Napoli, C 2008, 'Therapeutic dose of nebivolol, a nitric oxide-releasing β-blocker, reduces atherosclerosis in cholesterol-fed rabbits', Nitric Oxide - Biology and Chemistry, vol. 19, no. 1, pp. 57-63. https://doi.org/10.1016/j.niox.2008.03.004
de Nigris, Filomena ; Mancini, Francesco Paolo ; Balestrieri, Maria Luisa ; Byrns, Russell ; Fiorito, Carmela ; Williams-Ignarro, Sharon ; Palagiano, Antonio ; Crimi, Ettore ; Ignarro, Louis J. ; Napoli, Claudio. / Therapeutic dose of nebivolol, a nitric oxide-releasing β-blocker, reduces atherosclerosis in cholesterol-fed rabbits. In: Nitric Oxide - Biology and Chemistry. 2008 ; Vol. 19, No. 1. pp. 57-63.
@article{1b1c954dbbd34e52801fa15089c4b993,
title = "Therapeutic dose of nebivolol, a nitric oxide-releasing β-blocker, reduces atherosclerosis in cholesterol-fed rabbits",
abstract = "Nitric oxide (NO) exerts a plethora of vascular beneficial effects. The NO-releasing β-blocker nebivolol is a racemic mixture of d/l-enantiomers that displays negative inotropic as well as direct vasodilating activity. The in vivo antiatherogenic activity of therapeutic doses of the β-blocker with antioxidant properties carvedilol (12.5 mg/day) or nebivolol (5 mg/day) was tested in cholesterol-fed rabbits. Animals received a 1{\%} cholesterol-rich diet alone (controls) or mixed with drugs (treated animals) for 8 weeks. While it did not affect hyperlipidemia, nebivolol inhibited the development of atherosclerosis, expressed as computer-assisted imaging analysis of aortic area covered by lesions (23.3 ± 4.1{\%} in treated vs 38.2 ± 6.4{\%} in control animals, p <0.01). Differently, in our experimental condition of therapeutic drug doses, this antiatherogenic effect did not reach statistical significance in rabbits treated with carvedilol (32.5 ± 5.1{\%} aortic area covered by lesions, p = NS vs controls). Plasma nitrates increased in rabbits treated with nebivolol while both β-blockers reduced LDL oxidation. Moreover, nebivolol induced a consistent increase of endothelial reactivity and aortic eNOS expression compared with control animals (p <0.05) and those receiving carvedilol (p <0.05). Since NO may exert beneficial effects in atherosclerosis, a NO-dependent mechanism could explain this data. These observations suggest that the NO-releasing β-blocker, nebivolol, might represent an effective pharmacological approach for preventing atherosclerotic lesion progression.",
keywords = "Atherosclerosis, Carvedilol, Nebivolol, Nitric oxide, Rabbit",
author = "{de Nigris}, Filomena and Mancini, {Francesco Paolo} and Balestrieri, {Maria Luisa} and Russell Byrns and Carmela Fiorito and Sharon Williams-Ignarro and Antonio Palagiano and Ettore Crimi and Ignarro, {Louis J.} and Claudio Napoli",
year = "2008",
month = "8",
doi = "10.1016/j.niox.2008.03.004",
language = "English",
volume = "19",
pages = "57--63",
journal = "Nitric Oxide - Biology and Chemistry",
issn = "1089-8603",
publisher = "Academic Press Inc.",
number = "1",

}

TY - JOUR

T1 - Therapeutic dose of nebivolol, a nitric oxide-releasing β-blocker, reduces atherosclerosis in cholesterol-fed rabbits

AU - de Nigris, Filomena

AU - Mancini, Francesco Paolo

AU - Balestrieri, Maria Luisa

AU - Byrns, Russell

AU - Fiorito, Carmela

AU - Williams-Ignarro, Sharon

AU - Palagiano, Antonio

AU - Crimi, Ettore

AU - Ignarro, Louis J.

AU - Napoli, Claudio

PY - 2008/8

Y1 - 2008/8

N2 - Nitric oxide (NO) exerts a plethora of vascular beneficial effects. The NO-releasing β-blocker nebivolol is a racemic mixture of d/l-enantiomers that displays negative inotropic as well as direct vasodilating activity. The in vivo antiatherogenic activity of therapeutic doses of the β-blocker with antioxidant properties carvedilol (12.5 mg/day) or nebivolol (5 mg/day) was tested in cholesterol-fed rabbits. Animals received a 1% cholesterol-rich diet alone (controls) or mixed with drugs (treated animals) for 8 weeks. While it did not affect hyperlipidemia, nebivolol inhibited the development of atherosclerosis, expressed as computer-assisted imaging analysis of aortic area covered by lesions (23.3 ± 4.1% in treated vs 38.2 ± 6.4% in control animals, p <0.01). Differently, in our experimental condition of therapeutic drug doses, this antiatherogenic effect did not reach statistical significance in rabbits treated with carvedilol (32.5 ± 5.1% aortic area covered by lesions, p = NS vs controls). Plasma nitrates increased in rabbits treated with nebivolol while both β-blockers reduced LDL oxidation. Moreover, nebivolol induced a consistent increase of endothelial reactivity and aortic eNOS expression compared with control animals (p <0.05) and those receiving carvedilol (p <0.05). Since NO may exert beneficial effects in atherosclerosis, a NO-dependent mechanism could explain this data. These observations suggest that the NO-releasing β-blocker, nebivolol, might represent an effective pharmacological approach for preventing atherosclerotic lesion progression.

AB - Nitric oxide (NO) exerts a plethora of vascular beneficial effects. The NO-releasing β-blocker nebivolol is a racemic mixture of d/l-enantiomers that displays negative inotropic as well as direct vasodilating activity. The in vivo antiatherogenic activity of therapeutic doses of the β-blocker with antioxidant properties carvedilol (12.5 mg/day) or nebivolol (5 mg/day) was tested in cholesterol-fed rabbits. Animals received a 1% cholesterol-rich diet alone (controls) or mixed with drugs (treated animals) for 8 weeks. While it did not affect hyperlipidemia, nebivolol inhibited the development of atherosclerosis, expressed as computer-assisted imaging analysis of aortic area covered by lesions (23.3 ± 4.1% in treated vs 38.2 ± 6.4% in control animals, p <0.01). Differently, in our experimental condition of therapeutic drug doses, this antiatherogenic effect did not reach statistical significance in rabbits treated with carvedilol (32.5 ± 5.1% aortic area covered by lesions, p = NS vs controls). Plasma nitrates increased in rabbits treated with nebivolol while both β-blockers reduced LDL oxidation. Moreover, nebivolol induced a consistent increase of endothelial reactivity and aortic eNOS expression compared with control animals (p <0.05) and those receiving carvedilol (p <0.05). Since NO may exert beneficial effects in atherosclerosis, a NO-dependent mechanism could explain this data. These observations suggest that the NO-releasing β-blocker, nebivolol, might represent an effective pharmacological approach for preventing atherosclerotic lesion progression.

KW - Atherosclerosis

KW - Carvedilol

KW - Nebivolol

KW - Nitric oxide

KW - Rabbit

UR - http://www.scopus.com/inward/record.url?scp=46149088232&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=46149088232&partnerID=8YFLogxK

U2 - 10.1016/j.niox.2008.03.004

DO - 10.1016/j.niox.2008.03.004

M3 - Article

C2 - 18435936

AN - SCOPUS:46149088232

VL - 19

SP - 57

EP - 63

JO - Nitric Oxide - Biology and Chemistry

JF - Nitric Oxide - Biology and Chemistry

SN - 1089-8603

IS - 1

ER -